Trials / Completed
CompletedNCT00098033
Investigation of Clofarabine in Acute Leukemias
Phase II Clinical and Pharmacodynamic Investigation of Clofarabine in Acute Leukemias
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 64 (planned)
- Sponsor
- University of Texas · Academic / Other
- Sex
- All
- Age
- 12 Years
- Healthy volunteers
- Not accepted
Summary
The goals and objectives of this project are to evaluate the antileukemic activity of the investigational agent clofarabine in patients with acute myelogenous leukemia (AML), acute lymphocytic leukemia (ALL), and chronic myelogenous leukemia (CML) in accelerated and blastic phases.
Detailed description
The specific aims of the project are (1) conduct the phase II study of clofarabine and evaluate the antileukemic efficacy in AML, ALL, and CML-accelerated and blastic phases in terms of complete response (CR) rate, response duration, and survival; and (2) analyze the relationship between cellular uptake and retention of clofarabine triphosphate (the active metabolite), inhibition of DNA synthesis, and clinical outcome. Completion date provided represents the completion date of the grant per OOPD records
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | clofarabine |
Timeline
- Start date
- 2002-09-01
- Completion
- 2005-09-01
- First posted
- 2004-12-03
- Last updated
- 2015-03-25
Source: ClinicalTrials.gov record NCT00098033. Inclusion in this directory is not an endorsement.